Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01223378 · ClinicalTrials.gov registry record · Phase 2
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 413
- Enrollment target
NCT01223378 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 413 participants.
The verdict
NCT01223378, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 413 participants
- Enrollment target
Study Summary
The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
Interventions
- DRUG Latanoprost
- DRUG BOL-303259-X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2010-12-13 |
| Est. Completion | 2012-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01223378
The ClinicalTrials.gov registry entry for NCT01223378 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Latanoprost is the first listed.
NCT01223378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01223378 about?
NCT01223378 is a clinical study titled "Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension". The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
What is the current status of trial NCT01223378?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 413 participants. The study started on 2010-12-13. Estimated completion is 2012-06-22.
What interventions are being tested in trial NCT01223378?
The interventions under investigation include: Latanoprost (DRUG), BOL-303259-X (DRUG).
Who is sponsoring clinical trial NCT01223378?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.